The Promising Anti-Tumor Impact of Newcastle Disease Virus Expressing IL-2 and P53 Genes in Many Cancer Cell Lines In vitro

Abstract

Recombinant Newcastle disease virus (rNDV) has shown an anticancer effect in preclinical studies, but has never been tested in a lung cancer models. In this study we explored the anticancer activity of genetically modified NDV expressing IL-2-P53 (rClone30–IL-2-P53) in lung cancer model. We have cloned IL-2 and P53 genes and inserted them in the viral genome of New Castle Disease Virus to create a genetically modified rNDV- IL-2-P53 virus and tested the anti-tumor activity of the new virus in vitro on different types of cancer cell lines by MTT assay. TheIL-2 and P53 gene were successfully cloned and inserted into the viral genome by using a Mlu I and Sfi I endonucleases, viral vector was constructed correctly and successfully; sequencing results also showed that the recombinant plasmid was successfully constructed resulting in the formation of rClone30 NDV expressing both IL2 and P53 gene. In this study, P53 and IL-2 gene were successfully constructed into the NDV genome, by the use of reverse genetics technology, then successfully rescue of all recombinant rNDVclone30s and got high titer recombinant viruses.